Curcumin modulates the immune response associated with LPS-induced periodontal disease in rats.
Curcumin is a plant-derived dietary spice ascribed various biological activities. Curcumin therapeutic applications have been studied in a variety of conditions, but not on periodontal disease. Periodontal disease is a chronic inflammatory condition initiated by an immune response to micro-organisms of the dental biofilm. Experimental periodontal disease was induced in rats by injecting LPS in the gingival tissues on the palatal aspect of upper first molars (30 µg LPS, 3 times/week for 2 weeks). Curcumin was administered to rats daily via oral gavage at 30 and 100 mg/kg body weight. Reverse transcriptase-qPCR and ELISA were used to determine the expression of IL-6, TNF-α and prostaglandin E(2) synthase on the gingival tissues. The inflammatory status was evaluated by stereometric and descriptive analysis on hematoxylin/eosin-stained sections, whereas modulation of p38 MAPK and NK-κB signaling was assessed by Western blot. Curcumin effectively inhibited cytokine gene expression at mRNA and protein levels, but NF-κB was inhibited only with the lower dose of curcumin, whereas p38 MAPK activation was not affected. Curcumin produced a significant reduction on the inflammatory infiltrate and increased collagen content and fibroblastic cell numbers. Curcumin potently inhibits innate immune responses associated with periodontal disease, suggesting a therapeutic potential in this chronic inflammatory condition.
Department of Diagnosis and Surgery, Faculdade de Odontologia de Araraquara, Univ Estadual Paulista, Araraquara, SP, Brazil.
Morgana R
MR
Guimarães
Sabrina Garcia
SG
de Aquino
Leila S
LS
Coimbra
Luis C
LC
Spolidorio
Keith L
KL
Kirkwood
Carlos
C
Rossa
D000284:Administration, Oral; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology; D003474:Curcumin / Q000008:administration & dosage* / Q000009:adverse effects; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000187:drug effects / Q000276:immunology; D005881:Gingiva / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D006801:Humans; D015850:Interleukin-6 / Q000235:genetics / Q000378:metabolism; D019746:Intramolecular Oxidoreductases / Q000235:genetics / Q000378:metabolism; D008070:Lipopolysaccharides / Q000276:immunology; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D010510:Periodontal Diseases / Q000188:drug therapy* / Q000276:immunology; D000071876:Prostaglandin-E Synthases; D051381:Rats; D011919:Rats, Inbred Strains; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D015850:Interleukin-6; D008070:Lipopolysaccharides; D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; D019746:Intramolecular Oxidoreductases; D000071876:Prostaglandin-E Synthases; D003474:Curcumin
J Leukoc Biol. 2007 Oct;82(4):968-74
17609337
Mol Cell Biochem. 2009 Feb;322(1-2):127-35
19002562
J Periodontol. 2007 Mar;78(3):550-8
17335380
J Clin Immunol. 2008 Sep;28(5):558-70
18463970
Nature. 1997 Aug 7;388(6642):548-54
9252186
Science. 1997 Oct 31;278(5339):860-6
9346484
Arch Oral Biol. 2009 Jul;54(7):609-17
19393988
Cytokine Growth Factor Rev. 2009 Feb;20(1):7-17
19046922
Clin Exp Immunol. 2007 May;148(2):307-24
17355248
Eur J Pharmacol. 2008 Sep 28;593(1-3):105-11
18664365
J Biol Chem. 2006 Oct 13;281(41):31142-51
16914552
FEBS Lett. 2006 Jan 23;580(2):613-9
16406050
Biochem Pharmacol. 2006 May 14;71(10):1397-421
16563357
Nat Rev Cancer. 2003 Oct;3(10):768-80
14570043
J Immunol. 2005 Jun 15;174(12):8116-24
15944320
Mol Pharmacol. 2008 Feb;73(2):399-409
18006644
J Vet Med A Physiol Pathol Clin Med. 2006 Feb;53(1):49-54
16411910
J Clin Immunol. 2007 Jan;27(1):19-35
17211725
Am J Physiol Gastrointest Liver Physiol. 2003 Jan;284(1):G85-95
12488237